First SMA baby treated in Scotland
Analysis based on 12 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The successful early detection and treatment of SMA in United Kingdom — Scotland could accelerate adoption of newborn screening programmes, potentially expanding the market for SMA treatments. Novartis, as a funder and likely treatment provider, may see positive sentiment and increased demand for its SMA therapies.
The first baby identified through United Kingdom — Scotland's national in-service evaluation of newborn screening for spinal muscular atrophy (SMA) has started treatment. The baby was tested at five days old as part of the routine newborn blood spot test, and after a positive result, was referred to specialist services before symptoms developed. The screening programme, launched in March 2026, is the first of its kind in the UK and is funded by the Scotland — Scottish Government and Novartis. It aims to gather evidence for the United Kingdom — UK National Screening Committee to decide on permanent inclusion of SMA screening in the national newborn bloodspot programme. Early treatment can significantly improve outcomes for babies with SMA, a rare genetic condition causing progressive muscle weakness. The milestone demonstrates the real-life impact of early screening and highlights the value of the programme.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard